The approval removes the binary FDA risk and shifts focus to launch execution and IGNYTE-3 confirmatory trial enrollment (primary endpoint readout expected 2030). Monitor initial prescription trends and reimbursement dynamics over the next 60 days. The $150M offering at $12.06/share creates ~13% dilution but was necessary to fund commercialization.
Drug in focus
REPL drug pipeline →TUDRIQEV
● Neutral Named in this 8-K- Impact
- Phase
- Approved (Accelerated Approval)
- Time to market
- Already approved and commercially available in the U.S. since October 2026.
- Next catalyst
- None dated
What to watchTUDRIQEV is now a commercial-stage asset, so the focus shifts from regulatory binary to revenue execution. Watch the next quarterly earnings (likely late January 2027) for early sales figures, formulary adoption metrics, and the permanent J-code expected by April 2027. The confirmatory Phase 3 trial data timeline is the next major binary but has no announced readout date yet.
Price Chart
Executive Summary
Replimune reported fiscal Q1 2027 results with an in-line net loss of $69.8M ($-0.72 EPS), but the headline is the FDA accelerated approval of TUDRIQEV (RP1) on August 6, 2026, transforming the company into a commercial-stage biotech. A concurrent $150M financing extends cash runway beyond 12 months to support the U.S. launch within 60 days and the IGNYTE-3 confirmatory trial.
Key Financial Metrics
Key Facts
- FDA granted accelerated approval for TUDRIQEV (RP1) + nivolumab in advanced melanoma on August 6, 2026; launch within 60 days
- Net loss improved to $69.8M in Q1 FY2027 from $86.7M in the prior-year quarter
- EPS of $-0.72 matched consensus of $-0.72 (in-line)
- Cash, cash equivalents and short-term investments were $195.3M at June 30, 2026; plus $141M net proceeds from August offering extends runway >12 months
- Michelle DiNapoli appointed Chief Commercial Officer effective August 18, 2026
- R&D expenses decreased to $49.3M from $57.8M; SG&A decreased to $19.0M from $32.6M year-over-year
Financial Impact
Transformational: first approved product enables revenue generation; $150M financing ($141M net) provides capital for launch and confirmatory trial
Risk Factors
- Accelerated approval contingent on verification of clinical benefit in IGNYTE-3; failure could lead to withdrawal
- Commercial execution risk as a first-time product launcher
- Baker Brothers resale registration (S-3/A) creates ~30% overhang on common stock
- Competition from other oncolytic viruses and immunotherapies in melanoma
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-096483 |
| Document: tm2623208d1_8k.htm | 0001104659-26-096483 |
| Document: 0001104659-26-096483-index-headers.html | 0001104659-26-096483 |
| Document: 0001104659-26-096483-index.html | 0001104659-26-096483 |
| Document: 0001104659-26-096483.txt | 0001104659-26-096483 |
| 8-K Data (Synthetic) | 0001104659-26-096483 |
Track record
32 reports on REPL
9 of 13 bullish or bearish reports moved the stock their way by T+60. Best: +188.35% at T+20 after the Jul 30, 2026 report. 13 of 14 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $21.90 Now $21.41 −2.24% settles Feb 12
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $21.78 Now $21.41 −1.70% settles Feb 9
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
- Nov 6, 202610d ago 10-Q/A Neutral 3/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
- Nov 4, 202612d ago Institutional Cluster Bearish 4/10 Entry $20.69 Now $21.41 −3.48% settles Feb 2
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $20.69 Now $21.41 +3.48% settles Feb 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $20.65 Now $21.41 +3.68% settles Feb 1
- Oct 30, 202617d ago 144 Neutral 2/10 Entry $19.49 Now $21.41 +9.85% settles Jan 29
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers